“Intrinsically, there is nothing wrong with using Chinese CDMOs. But because of geopolitical issues, some large pharma want to have redundancy of that supply chain in the US.” Dr. Reza Oliyai, President and CEO of Oliyai Consulting Corporation, spent 28
AstraZeneca has announced a $15 billion investment in China through 2030 to expand medicines manufacturing and research and development capabilities, with a strategic focus on cell therapies and radioconjugates. The announcement came on Thursday, 29th January during UK Prime Minister
The 2026 J.P. Morgan Healthcare Conference revealed a shift in global pharmaceutical power dynamics, with China’s biotech sector commanding ever increasing attention from Western investors and executives who acknowledged the region’s transformation from manufacturing hub to innovation leader. You Cannot
Life sciences supply chains are moving out of China. This trend briefing, powered by SmartCube, summarises the key points you need to know.
